0001179110-20-002137.txt : 20200224
0001179110-20-002137.hdr.sgml : 20200224
20200224180450
ACCESSION NUMBER: 0001179110-20-002137
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200220
FILED AS OF DATE: 20200224
DATE AS OF CHANGE: 20200224
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ALBAN CARLOS
CENTRAL INDEX KEY: 0001474632
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35565
FILM NUMBER: 20646088
MAIL ADDRESS:
STREET 1: 1 N. WAUKEGAN ROAD
CITY: NORTH CHICAGO
STATE: IL
ZIP: 60064
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AbbVie Inc.
CENTRAL INDEX KEY: 0001551152
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 320375147
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1 NORTH WAUKEGAN ROAD
CITY: NORTH CHICAGO
STATE: IL
ZIP: 60064
BUSINESS PHONE: (847) 932-7900
MAIL ADDRESS:
STREET 1: 1 NORTH WAUKEGAN ROAD
CITY: NORTH CHICAGO
STATE: IL
ZIP: 60064
4
1
edgar.xml
FORM 4 -
X0306
4
2020-02-20
0
0001551152
AbbVie Inc.
ABBV
0001474632
ALBAN CARLOS
1 N. WAUKEGAN ROAD
NORTH CHICAGO
IL
60064
0
1
0
0
Vice Chairman
Common Stock, $0.01 par value
2020-02-20
4
A
0
39760
0
A
167637
D
Common Stock, $0.01 par value
2020-02-20
4
A
0
14340
0
A
181977
D
Common Stock, $0.01 par value
2020-02-20
4
A
0
8214
0
A
190191
D
Common Stock, $0.01 par value
2020-02-20
4
A
0
10125
0
A
200316
D
Common Stock, $0.01 par value
40442
I
Maria Cristina Alban 2007 Declaration of Trust
Option (right to buy)
93.50
2020-02-20
4
A
0
114566
0
A
2021-02-20
2030-02-19
Common Stock
114566
114566
D
Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.
Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.
Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.
Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020.
Held in the Maria Cristina Alban 2007 Declaration of Trust. The reporting person's spouse is trustee of the trust. The trust is revocable by his spouse. The reporting person disclaims beneficial ownership of these securities.
Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 38,189 on February 20, 2021, 38,189 on February 20, 2022, and 38,188 on February 20, 2023.
Steven L. Scrogham, attorney-in-fact for Carlos Alban
2020-02-24